Literature DB >> 6940212

New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.

T Oki, T Takeuchi, S Oka, H Umezawa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6940212     DOI: 10.1007/978-3-642-81565-2_4

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


× No keyword cloud information.
  15 in total

1.  Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

Authors:  P B Jensen; S K Larsen; I Stilbo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.

Authors:  J Schütte; N Niederle; S Seeber
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

5.  A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck.

Authors:  J L Eckenrode; R H Wheeler; A A Forastiere
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Comparative murine metabolism and disposition of class II anthracycline antibiotics.

Authors:  P Dodion; M J Egorin; C E Riggs; T A Ferraro; J M Tamburini; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma.

Authors:  K G Louie; T C Hamilton; B C Behrens; K R Grotzinger; W M McKoy; C E Myers; R C Young; R F Ozols
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.

Authors:  C Karanes; J D Young; M K Samson; L B Smith; L A Franco; L H Baker
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

10.  Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.

Authors:  S A Mortensen; H S Olsen; U Baandrup
Journal:  Br Heart J       Date:  1986-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.